Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study

HELP Study Investigators

doi:10.1111/cea.13974

Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study

HELP Study Investigators

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	1391-1395
Number of pages	5
Journal	Clinical and Experimental Allergy
Volume	51
Issue number	10
DOIs	https://doi.org/10.1111/cea.13974
State	Published - Oct 2021

Access to Document

10.1111/cea.13974

Cite this

@article{edc6196abf9e41f08f4f4126f033b811,

title = "Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study",

author = "{HELP Study Investigators} and Johnston, {Douglas T.} and Busse, {Paula J.} and Riedl, {Marc A.} and Marcus Maurer and John Anderson and Christina Nurse and Neil Inhaber and Ming Yu and Aleena Banerji and J. H{\'e}bert and B. Ritchie and G. Sussman and Yang, {W. H.} and {Escuriola Ettingshausen}, C. and M. Magerl and I. Martinez-Saguer and M. Maurer and P. Staubach and S. Zimmer and M. Cicardi and F. Perego and Wu, {M. A.} and A. Zanichelli and A. Al-Ghazawi and M. Shennak and Zaragoza-Urdaz, {R. H.} and R. Ghurye and Longhurst, {H. J.} and E. Zinser and J. Anderson and A. Banerji and Baptist, {A. P.} and Bernstein, {J. A.} and Boggs, {P. B.} and S. Christiansen and T. Craig and M. Davis-Lorton and S. Gierer and Gower, {R. G.} and D. Harris and Hong, {D. I.} and J. Jacobs and Johnston, {D. T.} and Levitch, {E. S.} and Li, {H. H.} and Lockey, {R. F.} and P. Lugar and Lumry, {W. R.} and Manning, {M. E.} and McNeil, {D. L.} and I. Melamed and T. Mostofi and T. Nickel and Otto, {W. R.} and Petrov, {A. A.} and K. Poarch and C. Radojicic and Rehman, {S. M.} and Riedl, {M. A.} and Schwartz, {L. B.} and R. Shapiro and E. Sher and Smith, {A. M.} and Smith, {T. D.} and D. Soteres and R. Tachdjian and Wedner, {H. J.} and Weinstein, {M. E.} and H. Zafra and Zuraw, {B. L.}",

note = "Funding Information: The HELP study was sponsored by Shire Human Genetic Therapies, Inc., a Takeda company, Lexington, MA, USA. Under direction of the authors, Shirley Teng, PhD, CMPP, employee of Excel Medical Affairs, provided writing assistance for this manuscript. Editorial assistance in formatting, proofreading, copy-editing and fact-checking also was provided by Excel Medical Affairs. Shire Human Genetic Therapies, Inc., a Takeda company, provided funding to Excel Medical Affairs for support in writing and editing this manuscript. We thank all patients, investigators and their study staff. We would like to acknowledge the late Dr Marco Cicardi, who was an Investigator for the HELP study and provided valuable insight into the interpretation of the study results. Funding Information: DTJ has received consulting/speaker fees from CSL Behring, Pharming and Shire (a Takeda company); and consulting fees from BioCryst and Regenxbio. PJB reports grants from Shire (a Takeda company); a lecture honorarium from CVS Health; and consulting fees from BioCryst, CSL Behring, Pearl Therapeutics, Pharming and Shire (a Takeda company). MAR has received research grants from BioCryst, CSL Behring, Pharming and Shire (a Takeda company); consulting fees from Adverum, Attune, BioCryst, CSL Behring, KalVista, Pharming, Pharvaris and Shire (a Takeda company); speaker honoraria from CSL Behring, Pharming and Shire; and is a medical advisory board member of the US Hereditary Angioedema Association. MM has received research grant support and/or speaker/consultancy fees from Adverum, Attune, BioCryst, CSL Behring, KalVista, Pharming, Pharvaris and Shire (a Takeda company). JA is a speaker bureau member for CSL Behring, Pharming, Biocryst and Shire (a Takeda company); has received consultancy fees from CSL Behring, Pharming and Shire (a Takeda company); and is a clinical trial investigator for Pharming, KalVista, BioCryst, CSL Behring and Shire (a Takeda company). CN, NI and MY are full‐time employees of Takeda Pharmaceutical Company Limited and hold stock/stock options in Takeda. AB has received institutional research/study support from BioCryst and Shire (a Takeda company) and/or honoraria for consulting from BioCryst, CSL Behring, KalVista, Pharming, Pharvaris and Shire (a Takeda company). Funding Information: The HELP study was sponsored by Shire Human Genetic Therapies, Inc., a Takeda company, Lexington, MA, USA. Under direction of the authors, Shirley Teng, PhD, CMPP, employee of Excel Medical Affairs, provided writing assistance for this manuscript. Editorial assistance in formatting, proofreading, copy‐editing and fact‐checking also was provided by Excel Medical Affairs. Shire Human Genetic Therapies, Inc., a Takeda company, provided funding to Excel Medical Affairs for support in writing and editing this manuscript. ",

year = "2021",

month = oct,

doi = "10.1111/cea.13974",

language = "English",

volume = "51",

pages = "1391--1395",

journal = "Clinical and Experimental Allergy",

issn = "0954-7894",

number = "10",

}

TY - JOUR

T1 - Effectiveness of lanadelumab for preventing hereditary angioedema attacks

T2 - Subgroup analyses from the HELP study

AU - HELP Study Investigators

AU - Johnston, Douglas T.

AU - Busse, Paula J.

AU - Riedl, Marc A.

AU - Maurer, Marcus

AU - Anderson, John

AU - Nurse, Christina

AU - Inhaber, Neil

AU - Yu, Ming

AU - Banerji, Aleena

AU - Hébert, J.

AU - Ritchie, B.

AU - Sussman, G.

AU - Yang, W. H.

AU - Escuriola Ettingshausen, C.

AU - Magerl, M.

AU - Martinez-Saguer, I.

AU - Maurer, M.

AU - Staubach, P.

AU - Zimmer, S.

AU - Cicardi, M.

AU - Perego, F.

AU - Wu, M. A.

AU - Zanichelli, A.

AU - Al-Ghazawi, A.

AU - Shennak, M.

AU - Zaragoza-Urdaz, R. H.

AU - Ghurye, R.

AU - Longhurst, H. J.

AU - Zinser, E.

AU - Anderson, J.

AU - Banerji, A.

AU - Baptist, A. P.

AU - Bernstein, J. A.

AU - Boggs, P. B.

AU - Christiansen, S.

AU - Craig, T.

AU - Davis-Lorton, M.

AU - Gierer, S.

AU - Gower, R. G.

AU - Harris, D.

AU - Hong, D. I.

AU - Jacobs, J.

AU - Johnston, D. T.

AU - Levitch, E. S.

AU - Li, H. H.

AU - Lockey, R. F.

AU - Lugar, P.

AU - Lumry, W. R.

AU - Manning, M. E.

AU - McNeil, D. L.

AU - Melamed, I.

AU - Mostofi, T.

AU - Nickel, T.

AU - Otto, W. R.

AU - Petrov, A. A.

AU - Poarch, K.

AU - Radojicic, C.

AU - Rehman, S. M.

AU - Riedl, M. A.

AU - Schwartz, L. B.

AU - Shapiro, R.

AU - Sher, E.

AU - Smith, A. M.

AU - Smith, T. D.

AU - Soteres, D.

AU - Tachdjian, R.

AU - Wedner, H. J.

AU - Weinstein, M. E.

AU - Zafra, H.

AU - Zuraw, B. L.

N1 - Funding Information: The HELP study was sponsored by Shire Human Genetic Therapies, Inc., a Takeda company, Lexington, MA, USA. Under direction of the authors, Shirley Teng, PhD, CMPP, employee of Excel Medical Affairs, provided writing assistance for this manuscript. Editorial assistance in formatting, proofreading, copy-editing and fact-checking also was provided by Excel Medical Affairs. Shire Human Genetic Therapies, Inc., a Takeda company, provided funding to Excel Medical Affairs for support in writing and editing this manuscript. We thank all patients, investigators and their study staff. We would like to acknowledge the late Dr Marco Cicardi, who was an Investigator for the HELP study and provided valuable insight into the interpretation of the study results. Funding Information: DTJ has received consulting/speaker fees from CSL Behring, Pharming and Shire (a Takeda company); and consulting fees from BioCryst and Regenxbio. PJB reports grants from Shire (a Takeda company); a lecture honorarium from CVS Health; and consulting fees from BioCryst, CSL Behring, Pearl Therapeutics, Pharming and Shire (a Takeda company). MAR has received research grants from BioCryst, CSL Behring, Pharming and Shire (a Takeda company); consulting fees from Adverum, Attune, BioCryst, CSL Behring, KalVista, Pharming, Pharvaris and Shire (a Takeda company); speaker honoraria from CSL Behring, Pharming and Shire; and is a medical advisory board member of the US Hereditary Angioedema Association. MM has received research grant support and/or speaker/consultancy fees from Adverum, Attune, BioCryst, CSL Behring, KalVista, Pharming, Pharvaris and Shire (a Takeda company). JA is a speaker bureau member for CSL Behring, Pharming, Biocryst and Shire (a Takeda company); has received consultancy fees from CSL Behring, Pharming and Shire (a Takeda company); and is a clinical trial investigator for Pharming, KalVista, BioCryst, CSL Behring and Shire (a Takeda company). CN, NI and MY are full‐time employees of Takeda Pharmaceutical Company Limited and hold stock/stock options in Takeda. AB has received institutional research/study support from BioCryst and Shire (a Takeda company) and/or honoraria for consulting from BioCryst, CSL Behring, KalVista, Pharming, Pharvaris and Shire (a Takeda company). Funding Information: The HELP study was sponsored by Shire Human Genetic Therapies, Inc., a Takeda company, Lexington, MA, USA. Under direction of the authors, Shirley Teng, PhD, CMPP, employee of Excel Medical Affairs, provided writing assistance for this manuscript. Editorial assistance in formatting, proofreading, copy‐editing and fact‐checking also was provided by Excel Medical Affairs. Shire Human Genetic Therapies, Inc., a Takeda company, provided funding to Excel Medical Affairs for support in writing and editing this manuscript.

PY - 2021/10

Y1 - 2021/10

UR - http://www.scopus.com/inward/record.url?scp=85113183008&partnerID=8YFLogxK

U2 - 10.1111/cea.13974

DO - 10.1111/cea.13974

M3 - Letter

C2 - 34166549

AN - SCOPUS:85113183008

SN - 0954-7894

VL - 51

SP - 1391

EP - 1395

JO - Clinical and Experimental Allergy

JF - Clinical and Experimental Allergy

IS - 10

ER -

Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study

Access to Document

Other files and links

Cite this